Statin Use for CVD Prevention Increases Diabetes Risk in Overweight Patients
Statin use was associated with increased rates of diabetes in overweight and obese patients.
There are no clear benefits or harms to choosing short-acting insulin analogs over regular human insulin for nonpregnant, adult individuals with type 2 diabetes.
Compared with GLP-1 receptor agonists, initiation of canagliflozin use for treatment of type 2 diabetes was not associated with increased risk for fracture.
Patients with T2D who initiated second-line antidiabetic medication therapy demonstrated similar CV risk after starting GLP-1 receptor agonists, SGLT-2 inhibitors, and DPP-4 inhibitors, which was below the threshold of harm.